Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey

Figures & data

Table 1. Demographic and clinical characteristics of patients who completed the survey.

Demographic and clinical characteristics	Survey respondents (n = 129)
Female, n (%)	85 (65.9%)
Country, n (%)
Spain	86 (66.7%)
Germany	43 (33.3%)
Years of age, mean (SD)	43.1 (12.9)
Age range, n (%)
18–34 years	40 (31.0%)
35–44 years	41 (31.8%)
45–54 years	24 (18.6%)
55–64 years	15 (11.6%)
≥65 years	9 (7.0%)
Years since psoriasis diagnosis, mean (SD)	12.2 (11.3)
Type of psoriasis, n (%)
Psoriasis	103 (79.8%)
Psoriasis + Psoriatic arthritis	26 (20.2%)
Percentage of BSA affected by psoriasis, mean (SD)	10.9 (15.4)
BSA categorical, n (%)
0–5%	71 (55.0%)
6–10%	27 (20.9%)
≥11%	31 (24.0%)
Number of body areas covered, mean (SD)	4.9 (3.2)
Affected body areas, n (%)
Scalp	82 (63.6%)
Ears	39 (30.2%)
Face	27 (20.9%)
Neck	22 (17.1%)
Elbows	75 (58.1%)
Hands	41 (31.8%)
Armpits	19 (14.7%)
Other areas of the arms	23 (17.8%)
Knees	52 (40.3%)
Feet	35 (27.1%)
Other areas of the legs	37 (28.7%)
Back	31 (24.0%)
Buttocks	22 (17.1%)
Abdomen	16 (12.4%)
Chest	18 (14.0%)
Gluteal cleft	13 (10.1%)
Genitals	14 (10.9%)
Navel	18 (14.0%)
Groins	14 (10.9%)
Fingernails	17 (13.2%)
Toenails	12 (9.3%)
Impact of psoriasis on QoL, n (%)
Very much	52 (40.3%)
Moderately	58 (45.0%)
Slightly	17 (13.2%)
Not at all	2 (1.6%)
Prior treatments for psoriasis*, n (%)
Topical	67 (51.9%)
Oral treatment	49 (38.0%)
Phototherapy/PUVA therapy	40 (31.0%)
Injectable treatment	30 (23.3%)
No treatment	16 (12.4%)
Other	4 (3.1%)
Current treatments for psoriasis*, n (%)
Topical	123 (95.3%)
Oral treatment	39 (30.2%)
Injectable treatment	31 (24.0%)
Phototherapy/PUVA therapy	9 (7.0%)
Other	3 (2.3%)

*Respondents were screened on their current or past use of CAL/BDP PAD-cream, therefore all had selected ‘topical’ as a current or past treatment.

BSA: body surface area; PUVA: psoralen plus ultraviolet A; QoL: quality of life; SD: standard deviation.

Figure 1. CAL/BDP PAD-cream use in real-world according to (A) daily frequency, (B) application location, (C) length of use and (D) waiting time before dressing after application.

Rounded percentages calculated based on the total number of patients who completed the survey (n = 129).

^aMean length of use was 14 weeks; ^bMean waiting time before dressing after application was 15 minutes.

CAL: calcipotriol; BDP: betamethasone dipropionate; PAD: polyaphron dispersion.

Figure 2. Percentage of patients who rated high agreement or complete agreement with each perception criterion, depending on whether it applied to CAL/BDP PAD-cream.

In the survey, each criterion could be rated by patients from 0 (‘do not agree at all’) to 10 (‘completely agree’). This figure only displays the percentage of patients who chose 8, 9, or 10 for each criterion. Rounded percentages calculated based on the total number of patients who completed the survey (n = 129).

CAL: calcipotriol; BDP: betamethasone dipropionate; PAD: polyaphron dispersion.

Figure 3. (A) Positive impact, (B) negative impact and (C) evaluation of CAL/BDP PAD-cream in a real-world setting.

Rounded percentages calculated based on the total number of patients who completed the survey (n = 129).

CAL: calcipotriol; BDP: betamethasone dipropionate; HCP: healthcare practitioner; PAD: polyaphron dispersion.

Figure 4. Comparison of CAL/BDP PAD-cream to the previous topical treatment used by patients.

Agree corresponds to overall positive responses (i.e., ‘agree’ and ‘strongly agree’). Disagree corresponds to overall negative responses (i.e., ‘disagree’ and ‘strongly disagree’). Rounded percentages calculated based on the total number of patients who had used a topical in the past (n = 67).

CAL: calcipotriol; BDP: betamethasone dipropionate; PAD: polyaphron dispersion.

Figure 5. Adherence with CAL/BDP PAD-cream assessed through (A) a visual analogue scale (VAS) and (B) the Morisky Medication Adherence Scale (MMAS-4).

Rounded percentages calculated based on the total number of patients who completed the survey (n = 129).

CAL: calcipotriol; BDP: betamethasone dipropionate; MMAS-4: Morisky Medication Adherence Scale; PAD: polyaphron dispersion; VAS: visual analogue scale.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.